Literature DB >> 27506378

Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical Trials.

Christopher L Jenkins1, Mark L Bagarazzi2, Hans-Peter Kiem3, Arnold J Levine4, Dale Ando5, Carl H June6, Tony Reid7, David W Emery8.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27506378      PMCID： PMC5088757          DOI： 10.1038/mt.2016.133

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  6 in total

1.  A tumultuous year for gene therapy.

Authors:  I M Verma
Journal:  Mol Ther       Date:  2000-11       Impact factor: 11.454

2.  Big changes coming to biosafety oversight of clinical gene transfer.

Authors:  David W Emery
Journal:  Mol Ther       Date:  2014-08       Impact factor: 11.454

3.  Charting a clear path: the ASGCT Standardized Pathways Conference.

Authors:  Hans-Peter Kiem; Christopher Baum; Frederic D Bushman; Barry J Byrne; Barrie J Carter; Joy Cavagnaro; Harry L Malech; Jerry R Mendell; Luigi M Naldini; Brian P Sorrentino; David A Williams; Terence R Flotte
Journal:  Mol Ther       Date:  2014-07       Impact factor: 11.454

4.  Innovation in the pharmaceutical industry: New estimates of R&D costs.

Authors:  Joseph A DiMasi; Henry G Grabowski; Ronald W Hansen
Journal:  J Health Econ       Date:  2016-02-12       Impact factor: 3.883

5.  Talimogene Laherparepvec: First Global Approval.

Authors:  Sarah L Greig
Journal:  Drugs       Date:  2016-01       Impact factor: 9.546

6.  T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Authors:  R M Blaese; K W Culver; A D Miller; C S Carter; T Fleisher; M Clerici; G Shearer; L Chang; Y Chiang; P Tolstoshev; J J Greenblatt; S A Rosenberg; H Klein; M Berger; C A Mullen; W J Ramsey; L Muul; R A Morgan; W F Anderson
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.